University of California, San Francisco
This is a single-arm, open-label, single-center, first-in-human feasibility study evaluating parenchymal blood volume (PBV) imaging as a tool to dynamically assess perfusional changes in hepatocellular carcinoma (HCC) potentiated by intra-arterial administration of nitroglycerin.
PRIMARY OBJECTIVES: I. Evaluate in vivo, parenchymal blood volume imaging's ability to dynamically assess blood flow to hepatocellular carcinoma. SECONDARY OBJECTIVES: 1\. Quantitative measurement of tumor perfusion after intra-arterial injection of nitroglycerin using parenchymal blood volume imaging. OUTLINE: Participants will undergo parenchymal blood volume (PBV) imaging before and after intra-arterial nitroglycerin injection during their standard transarterial chemoembolization (TACE) treatment. Participants will be followed on days 3, 7, 30, and 90 after the procedure.
Inclusion Criteria: 1. Participants must have radiographically documented, previously untreated LIRADS V liver lesions or biopsy-confirmed hepatocellular carcinoma (HCC), as determined by the ZSFG Liver Tumor Board. 2. Lesions must be determined to be suitable for conventional trans-arterial chemoembolization (cTACE) based on multidisciplinary tumor board review. 3. No prior locoregional therapy (e.g., TACE, Y-90) to the index lesion(s). 4. Age ≥18 years. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Karnofsky \>70%) 6. Demonstrates adequate organ function as defi…
Undergo imaging
Given Intra-Arterially
Data will be collected from the participant medical records.
Arctuva estimate
Verify or correct the compensation shown for this listing.